NCT01731886 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 31
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 60
- units
- Participants
- groups
- description
- Subjects will receive the current standard of care treatment. Lenalidomide and dexamethasone for four 28-day cycles followed by stem cell collection and autologous peripheral blood stem cell transplant. After 90 days, start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
- id
- BG000
- title
- Arm A: Low-dose Dexamethasone + Stem Cell Transplantation
- description
- Subjects will receive the new treatment that will be compared with the standard of care. Lenalidomide and dexamethasone for eight 28-day cycles. After four cycles your stem cells will be collected (stem cell collection). After an additional four cycles of lenalidomide (a total of 8 cycles), start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
- id
- BG001
- title
- Arm B: Low-dose Dexamethasone
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 39
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 21
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 27
- title
- Female
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 33
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 10
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 23
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 43
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 6
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 22
- title
- Stage 1(B2M <3.5 mg/L and serum albumin ≥3.5 g/dL)
- categories
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 28
- title
- Stage 2(Neither stage I nor stage III)
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 10
- title
- Stage 3(B2M ≥5.5 mg/L)
- param Type
- COUNT_OF_PARTICIPANTS
- title
- ISS Stage
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 31
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 60
- units
- Participants
- groups
- description
- Subjects will receive the current standard of care treatment. Lenalidomide and dexamethasone for four 28-day cycles followed by stem cell collection and autologous peripheral blood stem cell transplant. After 90 days, start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
- id
- BG000
- title
- Arm A: Low-dose Dexamethasone + Stem Cell Transplantation
- description
- Subjects will receive the new treatment that will be compared with the standard of care. Lenalidomide and dexamethasone for eight 28-day cycles. After four cycles your stem cells will be collected (stem cell collection). After an additional four cycles of lenalidomide (a total of 8 cycles), start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
- id
- BG001
- title
- Arm B: Low-dose Dexamethasone
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 39
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 21
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 27
- title
- Female
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 33
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 10
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 23
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 43
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 6
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 22
- title
- Stage 1(B2M <3.5 mg/L and serum albumin ≥3.5 g/dL)
- categories
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 28
- title
- Stage 2(Neither stage I nor stage III)
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 10
- title
- Stage 3(B2M ≥5.5 mg/L)
- param Type
- COUNT_OF_PARTICIPANTS
- title
- ISS Stage
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle